芦司他肽治疗骨髓增生异常综合征患者出现可逆性肺内血管扩张一例
一例70岁输血依赖型骨髓增生异常综合征患者在接受芦司他肽治疗9个月、剂量增加2个月后出现低氧血症,静息室内空气氧饱和度为88%。检查提示肺内分流(MAA闪烁显像分流7.5%),排除肝肺综合征及先天性门体分流后诊断为肺内血管扩张(IPVD),停用芦司他肽后7周停氧,10周后分流降至3.6%。
要点
- 芦司他肽治疗中出现的低氧血症需警惕IPVD可能。
- agitated saline超声心动图 late positive及MAA分流可提示肺内分流。
- 停用可疑药物后IPVD可逆,需监测血氧及分流变化。
核心结论
- 芦司他肽可能是骨髓增生异常综合征患者发生可逆性肺内血管扩张(IPVD)的原因。
研究设计与样本
- 单例病例报告:70岁男性输血依赖型骨髓增生异常综合征患者接受芦司他肽治疗。
主要发现
- 治疗9个月、剂量增加2个月后出现新发低氧血症,室内空气静息氧饱和度88%。
- 住院期间需高流量鼻导管高达90% Fio2维持饱和度≥92%。
- CT示稳定的轻度可能普通型间质性肺炎,无磨玻璃影、肺栓塞或动静脉畸形。
- agitated saline对比增强超声心动图 late positive,符合肺内分流。
- MAA分流闪烁显像显示分流7.5%。
关键数值与推荐
- 停用芦司他肽后7周停用补充氧疗。
- 停用后10周复查MAA确认分流消退(分流3.6%)。
临床怎么用
- 对接受芦司他肽治疗的患者应监测血氧饱和度,出现低氧血症时需评估肺内分流。
- 怀疑药物相关IPVD时,停用可疑药物后需随访氧合及分流变化。
局限性
- 单例病例报告,因果关系不能确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 70-year-old man with transfusion-dependent myelodysplastic syndrome was treated with luspatercept. Nine months into treatment and 2 months after dose increase, he developed new hypoxemia with a room air resting oxygen saturation of 88%. He was admitted, requiring up to 90% Fio2 by high-flow nasal cannula to maintain saturations ≥ 92%. CT scan demonstrated stable mild probable usual interstitial pneumonia, without ground-glass, pulmonary embolism, or arteriovenous malformation. Agitated saline contrast-enhanced echocardiogram was late positive, consistent with intrapulmonary shunt. Macroaggregated albumin (MAA) shunt scintigraphy demonstrated a shunt of 7.5%. Extensive investigations ruled out congenital portosystemic shunt and hepatopulmonary syndrome. We diagnosed hypoxemia from intrapulmonary vascular dilatation (IPVD), with luspatercept as a possible cause. Oxygen requirements improved, and supplemental oxygen was discontinued by 7 weeks after cessation. Repeat MAA 10 weeks after cessation confirmed shunt resolution (3.6% shunt). This case of reversible IPVD attributable to luspatercept highlights important monitoring implications in treated patients.
引用
- Al Lawati F, Gupta S, Faughnan ME, et al. Reversible Intrapulmonary Vascular Dilatation in a Patient Treated With Luspatercept for Myelodysplastic Syndrome. Chest. 2026. PMID: 42575657. doi:10.1016/j.chest.2026.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。